Q-omics provides the consensus-scored LRRN2 profile across patient tissues and cancer cell-line models. LRRN2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LRRN2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LRRN2 RNA expression shows 17,882 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where LRRN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRN2 survival associations across molecular data types. LRRN2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRN2 RNA expression–survival associations across cancer types. High LRRN2 expression shows unfavorable associations in UCEC, UVM, KIRP, BLCA and LIHC, but favorable associations in THYM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LRRN2 RNA expression.
This table summarizes LRRN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRN2 shows lower tumor expression in KIRC, COAD, KIRP and READ and higher tumor expression in LIHC and BRCA. The KIRC box plot shows higher LRRN2 RNA expression in normal versus tumor tissue (log2 FC = −3.202, t-test p < 0.001).
This table shows molecular features associated with LRRN2 in patient tissues and cancer cell lines. In patient samples, LRRN2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
